SNDX SYNDAX PHARMACEUTICALS

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 5, 2025 to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax1Q25

Domestic Dial-in Number: 800-590-8290

International Dial-in Number: 240-690-8800

Live webcast:

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on and .



Syndax Contact

Sharon Klahre

Syndax Pharmaceuticals, Inc.



Tel 781.684.9827



SNDX-G



EN
28/04/2025

Underlying

SNDXSYNDAX PHARMACEUTICALS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SYNDAX PHARMACEUTICALS

 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025 NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best New Drug Award recognizes excellence in pharmaceutical development and the drug that represents the best therapeutic advance in its area. Revuforj is a first-in-class menin inhibitor that was FDA in November 2024 for the treatment of relap...

December 12, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Mult...

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum – First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts – – Retrospective review shows revumenib was well tolerated as post-HSCT maintenance in children with KMT2Ar and NUP98r; all pts were alive and 90% (9/10) were relapse free at median follow-up of 19 months –  – Ph 2 SAVE tria...

December 8, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted inducement awards to purchase up to 15,500 shares of common stock to one new employee under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and ...

December 3, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Announces Participation at the 8th Annual Evercore Healthcare C...

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company's website at , where a replay will also be available f...

December 1, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 1, 2025, the Company granted inducement awards to purchase up to 143,500 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date a...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch